Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

@article{Mohler2011ActivationOT,
  title={Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.},
  author={James L. Mohler and Mark A. Titus and Suxia Bai and Brian J. Kennerley and Fred B Lih and Kenneth B. Tomer and Elizabeth M. Wilson},
  journal={Cancer research},
  year={2011},
  volume={71 4},
  pages={1486-96}
}
The androgen receptor (AR) mediates the growth of benign and malignant prostate in response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation therapy for prostate cancer, AR drives prostate cancer growth despite low circulating levels of testicular androgen and normal levels of adrenal androgen. In this report, we demonstrate the extent of AR transactivation in the presence of 5α-androstane-3α,17β-diol (androstanediol) in prostate-derived cell lines parallels the… CONTINUE READING
50 Citations
56 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

  • StanbroughM, GJ Bubley, K Ross, TR Golub, MA Rubin, TM Penning
  • Cancer Res
  • 2006
Highly Influential
16 Excerpts

Increased expression of genes converting adrenal androgens to testosterone in castration-recurrent prostate cancer

  • SP Balk
  • 2009

Similar Papers

Loading similar papers…